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Dr J. William Gaynor (Philadelphia, Pa). I have 2 questions.
First, is this marker expressed in tissues other than the brain? We
have seen problems with some other markers such as S100 ex-
pressed in other tissues that can be injured. Second, what is the
developmental expression? Obviously, I am interested in the im-
mature brain. Is it constant throughout development or is it in-
volved in control of development? Is the differential expressed
in the developing brain?
Dr Arnaoutakis. Thank you for those questions. I will address
your second point first. The candidate biomarkers that we have
looked at have been developed in tandem with our collaborators
in Gainesville, Florida, who specialize in proteomics, and so far
as they know, developmentally, the expression of this protein is
consistent.
Your first question is an especially important one because there
is the issue of confounding if these biomarkers are expressed in tis-
sues of organs that are not of interest.
UCH has 3 isoforms: L1, L2, and L3. The L1 isoform, as best
we can tell, is very specific to neurons. L2 and L3 have been iden-
tified in tumors but I do not believe they are expressed in normal
tissue. We do believe that UCHL1 is very specific. UCHL1 ac-
counts for about 5% of total soluble brain protein, which may
seem low, but given the gamut of the variety of brain proteins ex-
pressed, it is actually a very high amount. So we actually have seen
in other models, together with Dr Wang, that this seems to be a re-
producible and very specific biomarker.
DrMichael E. Jessen (Dallas, Tex). I enjoyed your talk. This is
a very important area for research. My question about this partic-
ular marker is how pragmatic it really is. It seems to me that you
have to deliver a pretty severe insult to the animal before you startrdiovascular Surgery c Volume 142, Number 4 909




Sto get defining amounts of the marker in the serum and in the CSF
as well. Does that detract from its clinical usefulness, whereas
what we really need is something that will be detected even
when subtle changes occur so that we would have the ability to
intervene?
Dr Arnaoutakis. That is a great point and I appreciate your
bringing that up. There are a couple of points to address in your
question. The animals that we have used in our model are young,
healthy, male dogs without any cerebrovascular disease or comor-
bidities. You are right that, to achieve damage, we have to subject
these animals to a rather profound insult. However, we do believe
that this has promise in humans who may have cerebrovascular
disease and comorbidities and would require a less severe insult
for this biomarker to be released. We think that these results sup-
port a follow-up study in humans in which we would evaluate the
serum.
The other point that you bring up is especially important in the
discussion of biomarkers. I know there are data both in the car-
diac surgery literature and in the critical care literature regarding
acute kidney injury biomarkers, for example, in which there are
actually profiles of biomarkers that enhance the sensitivity. We
have experience in our laboratory with biomarkers other than
UCHL1. Each has a limitation. Some are not as specific to the
brain as UCHL1 but are also expressed in higher levels with
less severe injury.
I think ultimately what we are looking for and what we would
aim to do with our human studies is not limit ourselves ahead of
time by only making preparations to study a single biomarker.
Rather, we would incorporate a panel so that we could increase
our sensitivity and not have to rely on any single biomarker to pre-
dict devastating neurologic injury, which is frequently manifest
clinically anyway.
Dr Jessen.How quickly can you get the results of an ELISA af-
ter you send the blood off so that you might have information on
which you would be able to intervene?910 The Journal of Thoracic and Cardiovascular SurgDr Arnaoutakis. Speaking to the logistics, at this point we are
collaborating with a laboratory in a different state. Having said
that, this laboratory has developed significant expertise with its
ELISA and its methods. Down the road, the intention is for this
to be used as a point of care test, so that it could actually be per-
formed either in the intensive care unit or in the critical laboratory,
making these results available in real time and allowing them to in-
form clinical decision making.
Dr Sunil P. Malhotra (New York, NY). Biomarkers of neuro-
logic injury are a very important area for cardiac surgery in gen-
eral. My question is this: You looked at 8 hours and 24 hours,
but I think it is important to evaluate the reversibility of brain in-
jury. Do you have any data on any long-term results, such as
a few days out, if the markers come down and if that correlates
with the canine score? Have you correlated this with any magnetic
resonance imaging or axial imaging of functional assessment of
brain injury?
Dr Arnaoutakis. Those are great points. The longest-term data
that we have is what I presented—24 hours. It is mainly for logis-
tical reasons through our animal care use committee and a canine
model. However, we actually have preparations for a longer-term
model to study these animals out to 1 week from their insult so that
we can glean better information regarding the time course profile
of these markers. From what we do have, it appears that the
UCHL1 is actually decreasing in the serum at least at 24 hours.
From the standpoint of damage, I know that the histologic char-
acteristics actually evolve over time such that at 8 hours, even after
2 hours of hypothermic circulatory arrest, there is not nearly as
much histologic damage as what we have seen in some of our
72-hour survival animals. The other interesting point related to
your question regarding longer term is that there may be bio-
markers that are expressed in the period of time 48 hours to even
1 week out from injury that may shed some light on longer-term
neurologic injury months down the road. That is an area that we
are investigating as well.ery c October 2011
